DEF 14A: Onconetix Seeks Stockholder Approval for Reverse Stock Split

Onconetix, Inc. is calling a special meeting of stockholders to vote on a reverse stock split proposal aimed at maintaining its Nasdaq listing and improving stock marketability.

Summary

• A Special Meeting of stockholders is scheduled for February 3, 2026, at 9:00 a.m. Eastern Time, at the offices of Ellenoff Grossman & Schole LLP in New York, NY.
• Stockholders will vote on two proposals: to approve an amendment to the Certificate of Incorporation to effect a reverse stock split, and to approve the adjournment of the Special Meeting if necessary to solicit additional proxies.
• The proposed reverse stock split would be at a ratio in the range of 1-for-2 to 1-for-50, with the exact ratio to be determined by the Board of Directors without further stockholder approval.
• The primary objective of the reverse stock split is to increase the per-share trading price of the Common Stock to regain or maintain compliance with Nasdaq's minimum bid price rule ($1.00 per share).
• Onconetix previously received a Nasdaq notice of non-compliance with the minimum bid price rule on January 23, 2025, and a further notice on April 14, 2025, regarding the Low Priced Stocks Rule (bid price of $0.10 or less).
• Following a hearing, Onconetix implemented a 1-for-85 reverse stock split on June 13, 2025, and regained Nasdaq compliance by July 7, 2025.
• The company is currently under a Mandatory Panel Monitor by Nasdaq through July 7, 2026, meaning any future non-compliance with the bid price rule would lead directly to a delisting determination without a 180-day grace period.
• The Board unanimously recommends that stockholders vote FOR both the Reverse Stock Split Proposal and the Adjournment Proposal.
• As of the record date, December 12, 2025, there were 1,555,015 shares of Common Stock outstanding and entitled to vote.

Sentiment

Score: 4

Explanation: The company is seeking approval for a reverse stock split primarily to address potential future non-compliance with Nasdaq's minimum bid price rule, following a previous 1-for-85 reverse split and a period of non-compliance. While the proposed action aims to prevent delisting and improve marketability, the necessity for such a measure indicates ongoing challenges with stock valuation and market perception, leading to a slightly negative sentiment.

Positives

• The reverse stock split has the potential to help Onconetix regain and maintain compliance with Nasdaq's minimum bid price rule, preventing delisting.
• An expected increase in the per-share market price of the Common Stock may improve its marketability and liquidity.
• A higher stock price could attract a broader range of investors, including institutional funds that have policies against investing in low-priced stocks.
• The action may encourage greater analyst and broker interest in the company's stock.
• Improving the stock's marketability and investor appeal could facilitate future capital-raising activities.

Negatives

• There is no assurance that the reverse stock split will result in a sustained increase in the Common Stock price for any meaningful period.
• The reduction in the total number of outstanding shares may lead to decreased trading volume and a smaller number of market makers, potentially reducing liquidity.
• Stockholders owning 'odd lots' (less than 100 shares) after the reverse stock split may incur incrementally higher transaction costs per share when selling.
• The market may view a reverse stock split negatively, potentially leading to a decrease in the company's overall market capitalization if the per-share price does not increase proportionally.
• Fractional shares will not be issued; instead, stockholders will receive cash, and they will not be entitled to receive interest for the period between the effective time and the payment date.

Risks

• Risk of future non-compliance with Nasdaq's minimum bid price rule ($1.00 per share), despite the proposed reverse stock split.
• The company is subject to a Mandatory Panel Monitor by Nasdaq through July 7, 2026, which means any failure to satisfy the Bid Price Rule during this period will result in a delisting determination without the usual 180-day grace period.
• Potential delisting from Nasdaq, which would likely result in the Common Stock trading on an over-the-counter market, leading to reduced liquidity, diminished analyst coverage, decreased investor interest, and impaired access to capital.
• The reverse stock split may not achieve its intended benefits, such as a sustained increase in stock price or improved liquidity.
• Stockholders who own less than 100 shares after the reverse stock split may face higher transaction costs if they sell their Common Stock.
• The reverse stock split could be viewed negatively by the market, potentially leading to a decrease in the company's overall market capitalization if the per-share price does not increase proportionally.

Future Outlook

The Board believes that implementing the reverse stock split, if approved, could increase the per-share market price, potentially improving marketability and liquidity of the Common Stock, encouraging trading, and attracting a broader range of investors. This action is intended to help the company maintain its Nasdaq listing and facilitate future capital-raising activities. However, there is no assurance that the reverse stock split will result in a sustained increase in the stock price or enhance the company's ability to raise capital. The company currently has no plans to issue additional shares made available by the split beyond existing commitments, such as those related to conversion/exercise rights and an equity line of credit from October 2024.

Management Comments

• "The Onconetix Board has unanimously determined and resolved that the Reverse Stock Split Proposal and the Adjournment Proposal are advisable and fair to, and in the best interests of, Onconetix and its stockholders, and has approved the Reverse Stock Split Amendment, subject to stockholder approval."
• "The Onconetix Board unanimously recommends that Onconetix stockholders vote FOR each of the foregoing proposals."
• "In order to prepare for the possibility that the Common Stock is not in compliance with the Bid Price Rule, the Board is requesting the stockholders to grant it the authority, at its discretion, to effect the Reverse Stock Split Amendment to regain compliance with the Bid Price Rule if required."
• "The Board further believes that should the Company implement the Reverse Stock Split Amendment, the expected increase in the market price of our Common Stock expected may improve marketability and liquidity of our Common Stock and may encourage trading."
• "If the Nasdaq Stock Market delists the Common Stock for failure to comply with applicable price-based listing requirements or otherwise, then the Common Stock would likely become traded on an over-the-counter market... interest in Common Stock may decline and certain institutions may not have the ability to trade in the Common Stock, all of which could have a material adverse effect on the liquidity or trading volume of the Common Stock."

Industry Context

This announcement reflects a common challenge faced by companies whose stock prices fall below exchange minimums. Nasdaq's listing rules, particularly the minimum bid price requirement, are standard for maintaining public market visibility and investor confidence. Reverse stock splits are a frequently employed corporate action to address such non-compliance, aiming to elevate the per-share price and avoid delisting. The mention of institutional investor policies against low-priced stocks highlights a broader market trend where certain funds are restricted from investing in 'penny stocks,' making higher stock prices desirable for attracting a wider investor base and improving market perception.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience a reduction in the number of shares held, with a proportional increase in per-share price (if successful). Fractional shares will be cashed out. Voting power remains proportionate. Potential for improved liquidity and marketability, but also risks of no sustained price increase, reduced liquidity, and higher transaction costs for odd lots.
• Employees: No direct impact on employees or employment mentioned in the filing.
• Customers: No direct impact on customers mentioned in the filing.
• Suppliers: No direct impact on suppliers mentioned in the filing.
• Creditors: No direct impact on creditors mentioned in the filing.

Next Steps

• Stockholders are to vote on the Reverse Stock Split Proposal and the Adjournment Proposal at the Special Meeting on February 3, 2026.
• If the Reverse Stock Split Proposal is approved, the Board will determine the final reverse split ratio (between 1-for-2 and 1-for-50) and the effective timing of the reverse stock split.
• The company will communicate additional details to the public if the reverse stock split is implemented.
• The Reverse Stock Split Amendment would become effective upon filing with the Delaware Secretary of State.
• The Board reserves the right to not proceed with the reverse stock split even if approved, or to abandon it if not implemented prior to the one-year anniversary of stockholder approval.
• The company will continue to be subject to a Mandatory Panel Monitor by Nasdaq until July 7, 2026.

Key Dates

Recommendation

The filing details a necessary corporate action to address potential future non-compliance with Nasdaq listing rules, following a previous reverse stock split and ongoing monitoring. While the reverse stock split aims to improve the stock's marketability and prevent delisting, it does not fundamentally alter the company's underlying business or financial performance. A seasoned investor would likely hold to observe the effectiveness of the reverse split in maintaining Nasdaq compliance and whether the company can address the underlying issues that led to the low stock price, rather than making a buy or sell decision based solely on this procedural proxy statement.

Keywords

Reverse Stock Split, Nasdaq Listing, Stockholder Meeting, Corporate Governance, Capital Raise, Share Price, Liquidity, Delisting Risk, Proxy Statement, Onconetix